These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 26580149)

  • 1. Long-term safety and activity of cladribine in patients with extranodal B-cell marginal zone lymphoma of the mucosa-associated lymphoid tissue (MALT) lymphoma.
    Kiesewetter B; Dolak W; Simonitsch-Klupp I; Mayerhoefer ME; Raderer M
    Hematol Oncol; 2017 Jun; 35(2):177-186. PubMed ID: 26580149
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue type with cladribine: a phase II study.
    Jäger G; Neumeister P; Brezinschek R; Hinterleitner T; Fiebiger W; Penz M; Neumann HJ; Mlineritsch B; DeSantis M; Quehenberger F; Chott A; Beham-Schmid C; Höfler G; Linkesch W; Raderer M
    J Clin Oncol; 2002 Sep; 20(18):3872-7. PubMed ID: 12228207
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Translocation t(11;18)(q21;q21) is not predictive of response to chemotherapy with 2CdA in patients with gastric MALT lymphoma.
    Streubel B; Ye H; Du MQ; Isaacson PG; Chott A; Raderer M
    Oncology; 2004; 66(6):476-80. PubMed ID: 15452377
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Delayed Efficacy After Treatment With Lenalidomide or Thalidomide in Patients With Mucosa-Associated Lymphoid Tissue Lymphoma.
    Kiesewetter B; Troch M; Mayerhoefer ME; Dolak W; Simonitsch-Klupp I; Raderer M
    Oncologist; 2016 Jan; 21(1):72-5. PubMed ID: 26621040
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cladribine combined with rituximab (R-2-CdA) therapy is an effective salvage therapy in relapsed or refractory indolent B-cell non-Hodgkin lymphoma.
    Nagai H; Ogura M; Kusumoto S; Takahashi N; Yamaguchi M; Takayama N; Kinoshita T; Motoji T; Ohyashiki K; Kosugi H; Matsuda S; Ohnishi K; Omachi K; Hotta T
    Eur J Haematol; 2011 Feb; 86(2):117-23. PubMed ID: 21070370
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rituximab for treatment of advanced extranodal marginal zone B cell lymphoma of the mucosa-associated lymphoid tissue lymphoma.
    Raderer M; Jäger G; Brugger S; Püspök A; Fiebiger W; Drach J; Wotherspoon A; Chott A
    Oncology; 2003; 65(4):306-10. PubMed ID: 14707449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rituximab plus subcutaneous cladribine in patients with extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue: a phase II study by the Arbeitsgemeinschaft Medikamentose Tumortherapie.
    Troch M; Kiesewetter B; Willenbacher W; Willenbacher E; Zebisch A; Linkesch W; Fridrik M; Müllauer L; Greil R; Raderer M
    Haematologica; 2013 Feb; 98(2):264-8. PubMed ID: 22983582
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Occurrence of a myelodysplastic syndrome (MDS) during first-line 2-chloro-deoxyadenosine (2-CDA) treatment of a low-grade gastrointestinal MALT lymphoma. Case report and review of the literature.
    Jäger G; Höfler G; Linkesch W; Neumeister P
    Haematologica; 2004 Apr; 89(4):ECR01. PubMed ID: 15075093
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prolonged clinical remission in patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type treated with cladribine: 6 year follow-up of a phase II trial.
    Jäger G; Neumeister P; Quehenberger F; Wöhrer S; Linkesch W; Raderer M
    Ann Oncol; 2006 Nov; 17(11):1722-3. PubMed ID: 16766585
    [No Abstract]   [Full Text] [Related]  

  • 10. A pilot phase II study of ofatumumab monotherapy for extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT) lymphoma.
    Kiesewetter B; Neuper O; Mayerhoefer ME; Dolak W; Lukas J; Simonitsch-Klupp I; Raderer M
    Hematol Oncol; 2018 Feb; 36(1):49-55. PubMed ID: 28695630
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prolonged follow-up on lenalidomide-based treatment for mucosa-associated lymphoid tissue lymphoma (MALT lymphoma)-Real-world data from the Medical University of Vienna.
    Kiesewetter B; Lamm W; Neuper O; Mayerhoefer ME; Simonitsch-Klupp I; Raderer M
    Hematol Oncol; 2019 Oct; 37(4):345-351. PubMed ID: 31283840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of gastric marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue with rituximab, cyclophosphamide, vincristine and prednisone.
    Aguiar-Bujanda D; Llorca-Mártinez I; Rivero-Vera JC; Blanco-Sánchez MJ; Jiménez-Gallego P; Mori-De Santiago M; Limeres-Gonzalez MA; Cabrera-Marrero JC; Hernández-Sosa M; Galván-Ruíz S; Hernández-Sarmiento S; Saura Grau S; Bohn-Sarmiento U
    Hematol Oncol; 2014 Sep; 32(3):139-44. PubMed ID: 24123108
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Complete remission of chronic plaque psoriasis and gastric marginal zone B-cell lymphoma of MALT type after treatment with 2-chlorodeoxyadenosine.
    Valencak J; Trautinger F; Fiebiger WC; Raderer M
    Ann Hematol; 2002 Nov; 81(11):662-5. PubMed ID: 12454707
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rituximab monotherapy as a first-line treatment for pulmonary mucosa-associated lymphoid tissue lymphoma.
    Okamura I; Imai H; Mori K; Ogura K; Isoda A; Mihara K; Matsumoto M; Saito R; Takahashi T; Ikeda T
    Int J Hematol; 2015 Jan; 101(1):46-51. PubMed ID: 25378228
    [TBL] [Abstract][Full Text] [Related]  

  • 15. T(11;18)-bearing pulmonary mucosa-associated lymphoid tissue lymphoma responding to cladribine.
    Kusumoto S; Kobayashi Y; Tanimoto TE; Hasegawa T; Yokota Y; Tanimoto K; Sekiguchi N; Narabayashi M; Watanabe T; Matsuno Y; Tobinai K
    Int J Hematol; 2004 Jul; 80(1):70-4. PubMed ID: 15293572
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Significant efficacy of 2-chlorodeoxyadenosine{+/-} rituximab in the treatment of splenic marginal zone lymphoma (SMZL): extended follow-up.
    Cervetti G; Galimberti S; Pelosini M; Ghio F; Cecconi N; Petrini M
    Ann Oncol; 2013 Sep; 24(9):2434-8. PubMed ID: 23712547
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination therapy with rituximab and intravenous or oral fludarabine in the first-line, systemic treatment of patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type.
    Salar A; Domingo-Domenech E; Estany C; Canales MA; Gallardo F; Servitje O; Fraile G; Montalbán C
    Cancer; 2009 Nov; 115(22):5210-7. PubMed ID: 19672998
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rituximab plus bendamustine is active in pretreated patients with extragastric marginal zone B cell lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma).
    Kiesewetter B; Mayerhoefer ME; Lukas J; Zielinski CC; Müllauer L; Raderer M
    Ann Hematol; 2014 Feb; 93(2):249-53. PubMed ID: 23925930
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibiotic treatment as sole management of Helicobacter pylori-negative gastric MALT lymphoma: a single center experience with prolonged follow-up.
    Raderer M; Wöhrer S; Kiesewetter B; Dolak W; Lagler H; Wotherspoon A; Muellauer L; Chott A
    Ann Hematol; 2015 Jun; 94(6):969-73. PubMed ID: 25579756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue of the head and neck area: high rate of disease recurrence following local therapy.
    Wenzel C; Fiebiger W; Dieckmann K; Formanek M; Chott A; Raderer M
    Cancer; 2003 May; 97(9):2236-41. PubMed ID: 12712477
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.